Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus
The Hill
by Joseph ChoiFebruary 24, 2026
AI-Generated Deep Dive Summary
Novo Nordisk has announced significant price reductions for its popular GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Rybelsus. Starting January 1, 2027, the list price for these drugs will be slashed by up to 50%, bringing the cost down to $675 across all three products in the U.S. This move is particularly impactful, as GLP-1 medications have become widely prescribed for both weight loss and diabetes management due to their effectiveness and popularity among patients and healthcare providers.
GLP-1 receptor agonists like semaglutide, which is the active ingredient in Ozempic, Wegovy, and Rybelsus, work by mimicking hormones that suppress appetite and slow digestion, leading to significant weight loss and improved blood sugar control. These drugs have revolutionized treatment for obesity and type 2 diabetes, with Wegovy alone becoming a blockbuster drug with annual sales exceeding $10 billion in recent years. However, their high cost has often been a barrier for patients, despite insurance coverage.
The decision to reduce prices comes amid growing pressure from competitors offering similar medications at lower costs, as well as increasing scrutiny of high drug prices in the U.S. healthcare system. Novo Nordisk’s price cut reflects a broader trend within the pharmaceutical industry to address concerns about affordability while maintaining profitability. The reduced list price is expected to make these treatments more accessible to patients, potentially improving health outcomes and reducing long-term healthcare costs.
Verticals
politicsnews
Originally published on The Hill on 2/24/2026